NCT03935685View on ClinicalTrials.gov

Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 26, 2019

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
Glioma of Brain
Interventions
DRUG

Mirtazapine (Remeron)

Eligible patients should start Mirtazapine 15mg and stay there unless not tolerated, If there is no improvement in nausea dose can be increased to 30 mg and respectively 45 mg, 4 days apart. If excessive sleep, dose can be doubled. Patients should not take tryptophan while they are part of the study.

Trial Locations (1)

92868

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

All Listed Sponsors
lead

University of California, Irvine

OTHER

NCT03935685 - Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ | Biotech Hunter | Biotech Hunter